Metformin treatment beneficial for obese children, teens

Metformin treatment beneficial for obese children, teens
Obese children and adolescents treated with twice-daily metformin have significantly improved body mass index standard deviation scores, fasting glucose, and other metabolic risk factors, according to research published online Nov. 21 in the Journal of Clinical Endocrinology & Metabolism.

(HealthDay)—Obese children and adolescents treated with twice-daily metformin have significantly improved body mass index standard deviation scores (BMI-SDS), fasting glucose, and other metabolic risk factors, according to research published online Nov. 21 in the Journal of Clinical Endocrinology & Metabolism.

Deborah Kendall, M.D., of the Royal Manchester Children's Hospital in the United Kingdom, and colleagues conducted a prospective, randomized, double-blind, placebo-controlled trial involving 151 obese children and adolescents from six pediatric endocrine centers to evaluate the effect of metformin, given at a dose of 1 g each morning and 500 mg each evening. Seventy-four participants were allocated to metformin and 77 were assigned to placebo for six months.

At three months, the researchers found that metformin-treated children and adolescents had significantly improved levels, alanine aminotransferase (ALT) levels, and adiponectin to leptin ratios (ALR) compared with placebo-treated participants. At six months, there were significant changes in BMI-SDS in metformin-treated participants compared with those who received placebo.

"The MOCA [Metformin in and Adolescents] trial provides evidence that a short treatment course of metformin is clinically useful, safe, and well tolerated to halt further gain in adiposity and improve fasting glucose, ALT, and ALR," the authors write. "Metformin may also provide a stimulus for further lifestyle changes and is a useful adjunct to support lifestyle modification and potentially reduce long-term risk of cardiovascular disease and type 2 diabetes."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Imeglimin beneficial as add-on to metformin in T2DM

Dec 14, 2012

(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, ...

Metformin may have dual effect in breast cancer

May 09, 2012

(HealthDay) -- For women without diabetes and with operable breast cancer, administration of metformin prior to surgery does not significantly affect the proliferative marker Ki-67 overall, but drug effects ...

Recommended for you

Syria hit by flesh-eating maggot disease

8 hours ago

Three cases of myiasis have been reported near Damascus, marking the first appearance of the flesh-eating maggot disease in Syria, UN health experts said Friday.

Sperm can carry Ebola for 82 days: WHO

10 hours ago

Sperm can carry the Ebola virus for at least 82 days, the World Health Organization said Friday, urging men recovering from the disease to use condoms for three months after the onset of symptoms.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.